Catalyzed by the paltry response to the pandemic and the inequities it is causing, people are flocking to graduate programs in public health to become the next front-line workers.
More than 246,000 people in the U.S. have been killed by the coronavirus, leaving hundreds of thousands of others grieving. Judith Graham, author of KHN’s Navigating Aging column, hosted a discussion on these unprecedented losses and dealing with bereavement. She was joined by Holly Prigerson, co-director of the Center for Research on End-of-Life Care at Weill Cornell Medicine in New York City, and Diane Snyder-Cowan, leader of the bereavement professionals steering committee of the National Council of Hospice and Palliative Professionals.
During the pandemic, shelters are having to change the way they do things to prevent the virus from spreading among the vulnerable homeless population. Now, as winter weather moves in, there’s less room at the shelters for those in need — threatening to leave many, literally, out in the cold.
As the coronavirus surges around the country, workers in nursing homes and assisted living centers are watching cases rise in long-term care facilities with a sense of dread. Many of these workers struggle with grief over the suffering they’ve witnessed.
Scientists have found that some people have antibodies against parts of their own immune system, allowing viruses to multiply rapidly.
While the Harvard Business School gently chided returnees to be on their best behavior, Stanford deployed green-vested enforcers and campus police who sometimes threatened students if they violated the rules. Both, apparently, succeeded.
COVID-19 can cause symptoms that go well beyond the lungs, from strokes to organ failure. To explain these widespread injuries, researchers are studying how the virus affects the vascular system.
Former Vice President Joe Biden is now the president-elect nearly everywhere but inside the Trump administration, where the president refuses to concede and has ordered officials not to begin a formal transition. That is a particular problem for health care as the COVID-19 pandemic surges. Meanwhile, there’s good news on the vaccine front, but it’s unlikely one will arrive by winter. And the ACA was back before the Supreme Court — again. Joanne Kenen of Politico, Stephanie Armour of The Wall Street Journal and Shefali Luthra of the 19th News join KHN’s Julie Rovner to discuss these issues and more. Plus, for extra credit, the panelists recommend their favorite health stories of the week they think you should read, too.
Dicen que hay que informar a los consumidores, para que se preparen para efectos secundarios que, en realidad, pueden significar que las vacunas funcionan.
From the likelihood of achy, flu-like side effects to the need for two doses, weeks apart, consumers need to know now what to expect when vaccines to prevent COVID-19 roll out.
Millions of people have lost their jobs and health insurance since March, and experts say many of those looking for a plan on the ACA marketplace may not be able to get the assistance they need.
The Trump administration hailed rapid tests as the way to halt COVID’s spread in nursing homes. A KHN analysis of federal data shows they’re not being used, as questions linger about accuracy and best practices.
Fear and uncertainty about the coronavirus have made online patient support groups fertile ground for the spread of misinformation. But some in these groups make fact-checking a part of the mission to support fellow COVID sufferers.
La farmacéutica anunció que en una muestra pequeña se comprobó que podría prevenir la infección en nueve de cada 10 casos. Pero se necesitan más respuestas.
The drugmaker says its mRNA vaccine worked in 90% of patients in its trial, but some observers question how long immunity will last and who will benefit.
Disneyland can’t reopen until Orange County’s coronavirus infection rates improve — especially among its poorest and most vulnerable residents. Local officials are protesting the requirements, saying the economy will suffer, and residents’ health along with it.
Human clinical trials are scheduled for a drug that could prevent some of the 100,000-plus deaths from snakebites worldwide each year. The same drug may also help people suffering from COVID-related acute respiratory distress.
It typically takes months to install new leadership, but with COVID deaths set to surge through the winter, many Democrats say Biden doesn’t have that sort of time.
Democrats had hoped not only to defeat President Donald Trump but also to capture the Senate so they could make major policy changes, such as bolstering the Affordable Care Act and reducing the number of uninsured.
Former Vice President Joe Biden remains on the cusp of being declared the winner of the presidential election, and which party will control the Senate next year remains in question. The outcomes of both the presidential and Senate elections will have dramatic effects on the health agenda. Meanwhile, should President Donald Trump eke out a win, his administration is still pushing some sweeping health changes. Joanne Kenen of Politico, Kimberly Leonard of Business Insider and Mary Ellen McIntire of CQ Roll Call join KHN’s Julie Rovner to discuss these issues and more.